1,140 Shares in Gilead Sciences, Inc. $GILD Acquired by Avalon Trust Co

Avalon Trust Co purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 1,140 shares of the biopharmaceutical company’s stock, valued at approximately $126,000.

Several other large investors also recently made changes to their positions in the stock. Brighton Jones LLC boosted its stake in Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after purchasing an additional 2,450 shares during the period. Bison Wealth LLC bought a new stake in shares of Gilead Sciences in the fourth quarter valued at about $215,000. Edgestream Partners L.P. lifted its holdings in shares of Gilead Sciences by 99.0% in the first quarter. Edgestream Partners L.P. now owns 18,401 shares of the biopharmaceutical company’s stock valued at $2,062,000 after purchasing an additional 9,152 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Gilead Sciences by 24.2% during the first quarter. Massachusetts Financial Services Co. MA now owns 94,286 shares of the biopharmaceutical company’s stock worth $10,565,000 after buying an additional 18,368 shares during the period. Finally, Parcion Private Wealth LLC bought a new position in shares of Gilead Sciences during the first quarter worth about $218,000. Institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on GILD shares. BMO Capital Markets boosted their target price on Gilead Sciences from $130.00 to $135.00 and gave the company an “outperform” rating in a research note on Monday, October 20th. Wells Fargo & Company boosted their price objective on shares of Gilead Sciences from $140.00 to $145.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Rothschild & Co Redburn increased their target price on shares of Gilead Sciences from $143.00 to $153.00 in a report on Monday. UBS Group raised their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research report on Friday, August 8th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and an average target price of $129.13.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $354,240.00. Following the completion of the sale, the insider owned 110,193 shares in the company, valued at $13,011,589.44. The trade was a 2.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Deborah H. Telman sold 53,646 shares of the stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $122.85, for a total transaction of $6,590,411.10. Following the transaction, the executive vice president owned 43,676 shares in the company, valued at approximately $5,365,596.60. The trade was a 55.12% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 94,646 shares of company stock worth $11,311,286 over the last ninety days. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Trading Up 1.5%

Shares of Gilead Sciences stock opened at $125.20 on Friday. The company has a market capitalization of $155.33 billion, a price-to-earnings ratio of 24.94, a P/E/G ratio of 0.81 and a beta of 0.32. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The business has a fifty day simple moving average of $117.24 and a two-hundred day simple moving average of $112.64. Gilead Sciences, Inc. has a 1 year low of $86.08 and a 1 year high of $127.68.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. During the same quarter in the prior year, the business earned $2.02 EPS. Gilead Sciences’s quarterly revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s dividend payout ratio is currently 48.99%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.